What the First Human Rapamycin Trials Found

For two decades, rapamycin has been one of the most consistent lifespan-extending compounds in animal research. In 2025, that finally started to translate into human data. In this episode of Beyond Healthspan, our clinical team — Brandon, Rich, and Brian — walks through every major human rapamycin study from the past year, including: - The PEARL trial: the first major human data on weekly low-dose rapamycin - Early cardiovascular benefits at low doses - Emerging research on long COVID and chronic fatigue - The mTOR pathway, explained simply - What animal studies (ITP) show vs. what we're now seeing in humans - Dosing and bioavailability: why more isn't always better - A year of safety data, explained - Trials to watch in 2026 and 2027 This isn't a hype reel. It's a clinical team going study by study through what we actually know now, what's still theoretical, and what's coming next. 🔬 Get started with rapamycin: https://www.gethealthspan.com/treatments/rapamycin?zp_type=product&zp_slug=rapamycin&zp_source=my_src&zp_campaign=my_campaign Disclaimer: This podcast is for educational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting or changing any treatment, including rapamycin.